Demographics and prevalence of positive QuantiFERON-TB Gold In-Tube test in renal transplant candidates

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Latent tuberculosis infection (LTBI) screening prior to solid organ transplantation is standard of care. QuantiFERON-TB Gold In-Tube (QFT-GIT) test is the preferred diagnostic test for renal transplant candidates (RTC). QFT-GIT reversions and the potential delay of living-donor kidney transplantation (LDKT) because of QFT-GIT positivity have not been examined previously in RTC. Methods: We evaluated the prevalence of positive QFT-GIT in RTC from January 1 through December 31, 2011. In addition, we examined the demographic and renal disease data differences between QFT-GIT-positive and -negative patients, changes in QFT-GIT results, and positive QFT-GIT results reverting to negative. Lastly, we evaluated if QFT-GIT-positive patients were less likely to undergo LDKT within 6 months of QFT-GIT testing. Results: In total, 722 RTC were analyzed, 16% of whom had positive QFT-GIT. The QFT-GIT-positive patients were more likely to be older and foreign-born, P <0.0001. Haitians had the highest prevalence. Of the 119 QFT-GIT-positive patients, 25% had low/intermediate-positive results and were more likely to revert to negative, compared with patients with high-positive QFT-GIT results (50% vs. 0%, P = 0.01). A trend was seen toward fewer QFT-GIT-positive patients undergoing LDKT, compared with QFT-GIT-negative patients (0% vs. 3%, P = 0.09). Conclusions: Our high prevalence was likely a result of the high number of foreign-born RTC. Half of our small subset of low/intermediate-positive QFT-GIT patients reverted to negative. QFT-GIT-positive patients were more likely to have their LDKT delayed.

Original languageEnglish (US)
Pages (from-to)5-13
Number of pages9
JournalTransplant Infectious Disease
Volume18
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Gold
Demography
Transplants
Kidney
Living Donors
Kidney Transplantation
Latent Tuberculosis
Organ Transplantation
Standard of Care
Routine Diagnostic Tests

Keywords

  • Latent tuberculosis
  • QuantiFERON-TB Gold In-Tube
  • Renal transplant candidates
  • Solid organ transplant

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Cite this

@article{bdbf0244887549c59de88440d29d6a49,
title = "Demographics and prevalence of positive QuantiFERON-TB Gold In-Tube test in renal transplant candidates",
abstract = "Background: Latent tuberculosis infection (LTBI) screening prior to solid organ transplantation is standard of care. QuantiFERON-TB Gold In-Tube (QFT-GIT) test is the preferred diagnostic test for renal transplant candidates (RTC). QFT-GIT reversions and the potential delay of living-donor kidney transplantation (LDKT) because of QFT-GIT positivity have not been examined previously in RTC. Methods: We evaluated the prevalence of positive QFT-GIT in RTC from January 1 through December 31, 2011. In addition, we examined the demographic and renal disease data differences between QFT-GIT-positive and -negative patients, changes in QFT-GIT results, and positive QFT-GIT results reverting to negative. Lastly, we evaluated if QFT-GIT-positive patients were less likely to undergo LDKT within 6 months of QFT-GIT testing. Results: In total, 722 RTC were analyzed, 16{\%} of whom had positive QFT-GIT. The QFT-GIT-positive patients were more likely to be older and foreign-born, P <0.0001. Haitians had the highest prevalence. Of the 119 QFT-GIT-positive patients, 25{\%} had low/intermediate-positive results and were more likely to revert to negative, compared with patients with high-positive QFT-GIT results (50{\%} vs. 0{\%}, P = 0.01). A trend was seen toward fewer QFT-GIT-positive patients undergoing LDKT, compared with QFT-GIT-negative patients (0{\%} vs. 3{\%}, P = 0.09). Conclusions: Our high prevalence was likely a result of the high number of foreign-born RTC. Half of our small subset of low/intermediate-positive QFT-GIT patients reverted to negative. QFT-GIT-positive patients were more likely to have their LDKT delayed.",
keywords = "Latent tuberculosis, QuantiFERON-TB Gold In-Tube, Renal transplant candidates, Solid organ transplant",
author = "Jacques Simkins-Cohen and K. Kraus and Morris, {Michele I}",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/tid.12476",
language = "English (US)",
volume = "18",
pages = "5--13",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Demographics and prevalence of positive QuantiFERON-TB Gold In-Tube test in renal transplant candidates

AU - Simkins-Cohen, Jacques

AU - Kraus, K.

AU - Morris, Michele I

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background: Latent tuberculosis infection (LTBI) screening prior to solid organ transplantation is standard of care. QuantiFERON-TB Gold In-Tube (QFT-GIT) test is the preferred diagnostic test for renal transplant candidates (RTC). QFT-GIT reversions and the potential delay of living-donor kidney transplantation (LDKT) because of QFT-GIT positivity have not been examined previously in RTC. Methods: We evaluated the prevalence of positive QFT-GIT in RTC from January 1 through December 31, 2011. In addition, we examined the demographic and renal disease data differences between QFT-GIT-positive and -negative patients, changes in QFT-GIT results, and positive QFT-GIT results reverting to negative. Lastly, we evaluated if QFT-GIT-positive patients were less likely to undergo LDKT within 6 months of QFT-GIT testing. Results: In total, 722 RTC were analyzed, 16% of whom had positive QFT-GIT. The QFT-GIT-positive patients were more likely to be older and foreign-born, P <0.0001. Haitians had the highest prevalence. Of the 119 QFT-GIT-positive patients, 25% had low/intermediate-positive results and were more likely to revert to negative, compared with patients with high-positive QFT-GIT results (50% vs. 0%, P = 0.01). A trend was seen toward fewer QFT-GIT-positive patients undergoing LDKT, compared with QFT-GIT-negative patients (0% vs. 3%, P = 0.09). Conclusions: Our high prevalence was likely a result of the high number of foreign-born RTC. Half of our small subset of low/intermediate-positive QFT-GIT patients reverted to negative. QFT-GIT-positive patients were more likely to have their LDKT delayed.

AB - Background: Latent tuberculosis infection (LTBI) screening prior to solid organ transplantation is standard of care. QuantiFERON-TB Gold In-Tube (QFT-GIT) test is the preferred diagnostic test for renal transplant candidates (RTC). QFT-GIT reversions and the potential delay of living-donor kidney transplantation (LDKT) because of QFT-GIT positivity have not been examined previously in RTC. Methods: We evaluated the prevalence of positive QFT-GIT in RTC from January 1 through December 31, 2011. In addition, we examined the demographic and renal disease data differences between QFT-GIT-positive and -negative patients, changes in QFT-GIT results, and positive QFT-GIT results reverting to negative. Lastly, we evaluated if QFT-GIT-positive patients were less likely to undergo LDKT within 6 months of QFT-GIT testing. Results: In total, 722 RTC were analyzed, 16% of whom had positive QFT-GIT. The QFT-GIT-positive patients were more likely to be older and foreign-born, P <0.0001. Haitians had the highest prevalence. Of the 119 QFT-GIT-positive patients, 25% had low/intermediate-positive results and were more likely to revert to negative, compared with patients with high-positive QFT-GIT results (50% vs. 0%, P = 0.01). A trend was seen toward fewer QFT-GIT-positive patients undergoing LDKT, compared with QFT-GIT-negative patients (0% vs. 3%, P = 0.09). Conclusions: Our high prevalence was likely a result of the high number of foreign-born RTC. Half of our small subset of low/intermediate-positive QFT-GIT patients reverted to negative. QFT-GIT-positive patients were more likely to have their LDKT delayed.

KW - Latent tuberculosis

KW - QuantiFERON-TB Gold In-Tube

KW - Renal transplant candidates

KW - Solid organ transplant

UR - http://www.scopus.com/inward/record.url?scp=84958654768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958654768&partnerID=8YFLogxK

U2 - 10.1111/tid.12476

DO - 10.1111/tid.12476

M3 - Article

VL - 18

SP - 5

EP - 13

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 1

ER -